Immunotherapy cancer advance
06 August 2010
Enclosing anticancer vaccines in virus-like cases may reduce their chances of being rejected by the immune system, researchers believe.
Therapeutic anticancer vaccines are designed to boost patients' anticancer immune response, but attempting to develop such therapies poses several challenges.
In particular, the viruses used to deliver antibodies are themselves targeted by the immune system, inducing neutralising and suppressive responses.
A team led by Dr Michael Morse of Duke University Medical Centre, North Carolina, has developed a method of overcoming these neutralising and suppressive responses, using an alphavirus packaged in virus-like particles.
Dr Morse and his colleagues found that repeated administration of these packaged antibodies induced clinically relevant, targeted immune responses. Such responses were also associated with longer overall patient survival, raising hopes that the approach may be of therapeutic benefit.
Additional Information
Latest jobs Jobs web feed
- Salaried GP The Practice plc £75-85k FTE +NHS pension, Ely or Leicester
- Regional Clinical Leads The Practice plc Salary £95-105k FTE + NHS pension, Leicester or Sheffield
- Salaried/Lead GPs Malling Health Competitive, role dependant, NHS Pension and defence fees reimbursed, Nationwide
- Locum GP's needed in the South Coast MSI Group Ltd £70 - £80 per hour, South Coast
- GP Locum, Lancashire Fresh Medical Recruitment £500 per day +, Lancashire Locum
- Locum GP's Required Surrey! Global Medics Locums £££ Up to £650 per day, Surrey
Most read
Most commented
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
